The sharp increase in Sangamo Therapeutics' consensus analyst price target is primarily driven by a significantly higher future P/E expectation, indicating greater anticipated earnings growth or improved sentiment, with the fair value rising from $2.62 to $4.10.
What's in the News
- CFO Prathyusha Duraibabu resigned, effective October 1, to join a private AI company; no disagreements cited in her departure.
- Detailed Phase 1/2 STAAR study data presented for isaralgagene civaparvovec (ST-920) in Fabry disease showed positive mean annualized eGFR slope across 32 patients; therapy holds multiple regulatory designations from FDA, EMA, and UK MHRA.
- Positive topline results from STAAR study: at 104 weeks, 19 patients dosed with ST-920 had a positive mean annualized eGFR slope, comparing favorably to approved Fabry disease treatments; further analyses and presentations expected.
- The company faces significant risks related to insufficient capital resources, necessity of further funding, and potential operational discontinuity if funding or partners are not secured.
Valuation Changes
Summary of Valuation Changes for Sangamo Therapeutics
- The Consensus Analyst Price Target has significantly risen from $2.62 to $4.10.
- The Future P/E for Sangamo Therapeutics has significantly risen from 49.77x to 77.77x.
- The Discount Rate for Sangamo Therapeutics remained effectively unchanged, moving only marginally from 6.91% to 6.93%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.